ABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Skin Diseases, Vesiculobullous/etiology , Coma/complicationsSubject(s)
Chilblains , Coronavirus Infections , Pandemics , Pneumonia, Viral , Betacoronavirus , COVID-19 , Humans , Middle East , SARS-CoV-2Subject(s)
Acute Generalized Exanthematous Pustulosis/etiology , Cephalosporins/adverse effects , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Pneumonia, Viral/diagnosis , Pneumonia, Viral/drug therapy , Severe Acute Respiratory Syndrome/drug therapy , Acute Generalized Exanthematous Pustulosis/diagnosis , Acute Generalized Exanthematous Pustulosis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Biopsy, Needle , COVID-19 , COVID-19 Testing , Cephalosporins/therapeutic use , Clinical Laboratory Techniques , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Immunohistochemistry , Middle Aged , Obesity, Morbid , Pandemics/statistics & numerical data , Severe Acute Respiratory Syndrome/diagnosis , Severity of Illness Index , Treatment OutcomeABSTRACT
El dupilumab es un fármaco de reciente aprobación por la Food and Drug Administration (FDA) y la European Medical Agency (EMA) para el tratamiento de la dermatitis atópica moderada-severa en adultos. El incremento de la frecuencia de conjuntivitis asociadas a dupilumab ha sido expuesto en publicaciones y ensayos recientes. Presentamos 2 casos de conjuntivitis corticodependiente tratados satisfactoriamente con ciclosporina al 0,1% (Ikervis(R)). No hay casos previos descritos de conjuntivitis asociada a dupilumab tratados con ciclosporina al 0,1% (Ikervis(R))
Dupilumab is a drug that has recently been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for the treatment of moderate-to-severe atopic dermatitis in adults. An increase in frequency of conjunctivitis related to dupilumab treatment has been reported in recent publications and clinical trials. We report two steroid-dependent cases satisfactorily treated with cyclosporine 0.1% (Ikervis(R)). To our knowledge there are no reported cases of dupilumab-associated conjunctivitis treated with cyclosporine 0.1% (Ikervis(R)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Antibodies, Monoclonal, Humanized/adverse effects , Conjunctivitis/chemically induced , Conjunctivitis/drug therapy , Cyclosporine/therapeutic use , Dermatitis, Atopic/drug therapy , Immunosuppressive Agents/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Conjunctivitis/diagnostic imaging , Fluorometholone/therapeutic use , Glucocorticoids/therapeutic use , Interleukin-4 Receptor alpha Subunit , RecurrenceABSTRACT
Dupilumab is a drug that has recently been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for the treatment of moderate-to-severe atopic dermatitis in adults. An increase in frequency of conjunctivitis related to dupilumab treatment has been reported in recent publications and clinical trials. We report two steroid-dependent cases satisfactorily treated with cyclosporine 0.1% (Ikervis®). To our knowledge there are no reported cases of dupilumab-associated conjunctivitis treated with cyclosporine 0.1% (Ikervis®).
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Conjunctivitis/chemically induced , Conjunctivitis/drug therapy , Cyclosporine/therapeutic use , Dermatitis, Atopic/drug therapy , Immunosuppressive Agents/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Adult , Conjunctivitis/diagnostic imaging , Female , Fluorometholone/therapeutic use , Glucocorticoids/therapeutic use , Humans , Interleukin-4 Receptor alpha Subunit , Male , Middle Aged , RecurrenceABSTRACT
Un varón caucásico de 44 años con antecedentes de psoriasis en placa en tratamiento actualmente con ustekinumab se presentó con una pérdida brusca de visión en su ojo izquierdo. El examen de fondo de ojo mostró una oclusión de la vena central de la retina que coexistía con una oclusión de la arteria central de la retina. Estudios posteriores revelaron una leve policitemia, siendo la causa subyacente desconocida
A 44 year-old Caucasian male with a history of plaque psoriasis currently being treated with ustekinumab presented with sudden loss of vision in his left eye. Fundus examination showed central retinal vein occlusion coexisting with central retinal artery occlusion. Posterior examination revealed mild polycythemia, being the underlying cause unknown
Subject(s)
Humans , Male , Adult , Psoriasis/complications , Retinal Artery Occlusion/etiology , Retinal Vein Occlusion/etiology , Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Ustekinumab/therapeutic useABSTRACT
A 44 year-old Caucasian male with a history of plaque psoriasis currently being treated with ustekinumab presented with sudden loss of vision in his left eye. Fundus examination showed central retinal vein occlusion coexisting with central retinal artery occlusion. Posterior examination revealed mild polycythemia, being the underlying cause unknown.
